MedinCell S.A.
MedinCell S.A. (MDCLF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mdclf · pe ratio · data through Mar 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for MedinCell S.A. (MDCLF) measures how much investors pay for each dollar of the company's trailing earnings. MDCLF's current PE ratio of N/A is calculated by dividing its stock price of $34.39 by its TTM earnings per share of -$0.60.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-03-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
MedinCell S.A.You MDCLF | $1.2B | N/A | — | -$0.60 |
 Avacta Group Plc AVCTF | $437M | N/A | — | -$0.10 |
 BioInvent International AB (publ) BOVNF | $436M | N/A | — | -$5.05 |
 CytoDyn Inc. CYDY | $409M | 109.11x | — | $0.00 |
 GenSight Biologics S.A. GSGTF | $31M | N/A | — | -$0.08 |
 Healios K.K. HLOSF | $291M | N/A | — | -$20.61 |
 Northwest Biotherapeutics, Inc. NWBO | $326M | N/A | — | -$0.04 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-03-31Latest FY2025 | — | $-0.63 | — | |
2024-03-31 FY2024 | — | $-0.88 | — | |
2023-03-31 FY2023 | — | $-1.27 | — | |
2022-03-31 FY2022 | — | $-1.00 | — | |
2021-03-31 FY2021 | — | $-0.86 | — | |
2020-03-31 FY2020 | — | $-1.19 | — | |
2019-03-31 FY2019 | — | $-1.14 | — | |
2018-03-31 FY2018 | — | $-0.66 | — | |
2017-03-31 FY2017 | — | $-0.25 | — | |
2016-03-31 FY2016 | 379.95x | $0.04 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for MedinCell S.A. (MDCLF) measures how much investors pay for each dollar of the company's trailing earnings. MDCLF's current PE ratio of N/A is calculated by dividing its stock price of $34.39 by its TTM earnings per share of -$0.60.
Frequently asked questions
MDCLF pe ratio · 6 questionsMDCLF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $34.39 and TTM EPS of -$0.60. Data sourced from Financial Modeling Prep via MDCLF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MedinCell S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09